AnaptysBio Inc (OQ:ANAB)

Jan 08, 2020 04:00 pm ET
AnaptysBio to Present at J.P. Morgan Annual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Nov 08, 2019 08:05 am ET
AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended September 30,...
Nov 08, 2019 08:00 am ET
AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized,...
Sep 30, 2019 04:15 pm ET
AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced positive topline data from an interim analysis of its...
Sep 27, 2019 06:30 am ET
AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Aug 08, 2019 04:15 pm ET
AnaptysBio Announces Second Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the second quarter ended June 30,...
Aug 06, 2019 06:30 am ET
AnaptysBio to Present at the Wedbush PacGrow 2019 Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Jun 05, 2019 07:00 am ET
AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today presented updated proof-of-concept data for etokimab, its...
May 28, 2019 06:55 am ET
AnaptysBio to Present at the Jefferies 2019 Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
May 07, 2019 04:15 pm ET
AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the first quarter ended March 31,...
May 01, 2019 06:30 am ET
AnaptysBio to Present at the Bank of America Merrill Lynch Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Mar 04, 2019 06:30 am ET
AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Feb 28, 2019 05:45 am ET
AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the fourth quarter and year ended...
Jan 02, 2019 06:30 am ET
AnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Nov 26, 2018 08:00 am ET
Research Report Identifies Ebix, Gold Resource, Mastech Digital, AmeriGas Partners, Tactile Systems Technology, and AnaptysBio with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ebix, Inc. (NASDAQ:EBIX), Gold Resource Corporation (NYSE:GORO), Mastech...
Nov 08, 2018 04:15 pm ET
AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended September 30,...
Nov 05, 2018 06:30 am ET
AnaptysBio to Participate in Upcoming Investor Conferences
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Oct 08, 2018 07:30 am ET
Research Report Identifies AnaptysBio, Imperial Oil, Norbord, 3D, Apple Hospitality REIT, and Pinnacle Foods with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AnaptysBio, Inc. (NASDAQ:ANAB), Imperial Oil Limited (NYSE:IMO), Norbord...
Sep 28, 2018 04:05 pm ET
AnaptysBio Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option
AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the closing of its underwritten public offering of...
Sep 25, 2018 07:49 pm ET
AnaptysBio Announces Pricing of Public Offering of Common Stock
AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the pricing of its underwritten public offering of...
Sep 24, 2018 04:01 pm ET
AnaptysBio Announces Proposed Public Offering of Common Stock
AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that it intends to offer $200.0 million of its common...
Sep 24, 2018 06:30 am ET
AnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced positive topline proof-of-concept data for etokimab, its...
Aug 07, 2018 06:30 am ET
AnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the second quarter ended June 30,...
Aug 06, 2018 06:30 am ET
AnaptysBio to Present at the 2018 Wedbush PacGrow Healthcare Conference
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
Jul 25, 2018 07:50 am ET
Report: Exploring Fundamental Drivers Behind Martin Midstream Partners, AnaptysBio, Bright Horizons Family Solutions, Masonite International, Digimarc, and Cohu — New Horizons, Emerging Trends, and Up
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Martin Midstream Partners L.P. (NASDAQ:MMLP), AnaptysBio, Inc....
May 30, 2018 06:30 am ET
AnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference
AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio,...
May 29, 2018 08:30 am ET
AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress
AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that updated data from the company’s Phase 2a trial of...
May 18, 2018 08:25 am ET
Market Trends Toward New Normal in Castlight Health, inc, Marriot Vacations Worldwide, AnaptysBio, Compass Diversified, Triumph, and Asbury Automotive Group — Emerging Consolidated Expectations, Analy
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Castlight Health, inc. (NYSE:CSLT), Marriot Vacations Worldwide...
May 08, 2018 04:15 pm ET
AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates
AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the first quarter ended March 31, 2018...
May 01, 2018 06:30 am ET
AnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI Congress
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that clinical data for its ANB020 and ANB019 programs...
Apr 27, 2018 06:30 am ET
AnaptysBio To Participate in Upcoming Investor Conferences
SAN DIEGO, April 27, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that that company will participate in the following investor...
Mar 26, 2018 04:05 pm ET
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients
SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced top-line proof-of-concept data from an interim analysis of an...
Mar 20, 2018 07:40 am ET
Analysis: Positioning to Benefit within AnaptysBio, MoSys, CONMED, Franklin Financial Network, Hersha Hospitality Trust, and Inovalon — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AnaptysBio, Inc. (NASDAQ:ANAB), MoSys, Inc. (NASDAQ:MOSY),...
Mar 05, 2018 04:15 pm ET
AnaptysBio Announces Fourth Quarter and Full Year 2017 Financial Results and 2018 Pipeline Milestones
ANB020 Top-Line Phase 2a Readouts Anticipated For Peanut Allergy in March 2018 and Eosinophilic Asthma in Second Quarter 2018
Feb 17, 2018 05:00 pm ET
AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting
SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that updated data from the company’s Phase 2a trial...
Feb 07, 2018 06:30 am ET
AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting
SAN DIEGO, Feb. 07, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that data from the company’s Phase 2a trial of...
Jan 18, 2018 07:40 am ET
Investor Expectations to Drive Momentum within Martin Marietta Materials, AnaptysBio, Hope, Agilysys, Albany International, and Goldman Sachs BDC — Discovering Underlying Factors of Influence
NEW YORK, Jan. 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Martin Marietta Materials, Inc. (NYSE:MLM), AnaptysBio,...
Jan 02, 2018 06:30 am ET
AnaptysBio Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference
SAN DIEGO, Jan. 02, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will...
Nov 07, 2017 06:00 am ET
AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates
Announced Positive Proof-of-Concept Data for ANB020 in Atopic Dermatitis...
Nov 07, 2017 06:00 am ET
AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates
Announced Positive Proof-of-Concept Data for ANB020 in Atopic Dermatitis
Nov 06, 2017 04:15 pm ET
AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results
Robust Half-Life and Extended Pharmacodynamic Activity Following a Single Dose of ANB019...
Nov 06, 2017 04:15 pm ET
AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results
Robust Half-Life and Extended Pharmacodynamic Activity Following a Single Dose of ANB019
Oct 10, 2017 04:20 pm ET
AnaptysBio Files Registration Statement for Proposed Public Offering
SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that it intends to offer and sell 3,000,000 shares of its common stock in an underwritten public offering. In addition, AnaptysBio intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offerin...
May 11, 2017 04:30 pm ET
AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported first quarter 2017 financial results and provided a pipeline update....
Apr 06, 2017 08:00 am ET
AnaptysBio Announces First-In-Human Dosing of ANB019
SAN DIEGO, April 06, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced first-in-human dosing of its wholly-owned proprietary anti-Interleukin-36 receptor (IL-36R) antibody, ANB019, in a healthy volunteer Phase 1 clinical trial. The double-blind, placebo-controlled, single and multiple ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ANB019 through subcutaneous and in...
Mar 08, 2017 04:30 pm ET
AnaptysBio Announces 2016 Operating Results and Pipeline Progress
SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced progress on the Company’s product pipeline, business highlights and reported full year 2016 financial results....
Mar 04, 2017 03:00 pm ET
AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting
SAN DIEGO, March 04, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that its scientific collaborators at the Benaroya Research Institute at Virginia Mason (BRI) have presented a translational research study entitled “Role of IL-33 in modulating human allergen-specific pathogenic CD4+T Cell responses,” at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting (Session Number 2604, Presentation Number ...
Jan 31, 2017 05:00 pm ET
AnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Jan. 31, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the closing of its initial public offering of 5,750,000 shares of its common stock at a public offering price of $15.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares of common stock. The shares began trading on The NASDAQ Global Select Market on January 26, 2017 under the symbol “ANAB....
Jan 25, 2017 07:00 pm ET
AnaptysBio Announces Pricing of Initial Public Offering
SAN DIEGO, Jan. 25, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15 per share. The shares are expected to begin trading on The NASDAQ Global Select Market on January 26, 2017, under the symbol "ANAB." In addition, AnaptysBio has granted the underwriters a 30-day option to purchase up to an additional 750,000 sha...